vexed's Journey with Lymphoplasmacytic Lymphoma (Waldenstr...

Patient: Non-Hodgkin Lymphoma (NHL) > B-Cell Lymphoma > Lymphoplasmacytic Lymphoma (Waldenstrom Macroglobulinemia)

Patient Info: Newly diagnosed (has not begun treatment), Diagnosed: about 9 years ago, Male, Age: 71

  1. 1
    • vexed
    • Experience with Lymphoplasmacytic Lympho...
    over 5 years ago
    vexed's Avatar

    Oh No

    This person has yet to add any details about this experience.

    1 Comment
  2. 2
    • vexed
    • Experience with Lymphoplasmacytic Lympho...
    over 5 years ago
    vexed's Avatar

    Bleeding

    Side Effects

    Abnormal blood counts (RBC, WBC, platelets, hemoglobin) sufficient to cause some side effects but not (yet) low enough to provoke treatment.

    0 Comments
  3. 3
    • vexed
    • Experience with Lymphoplasmacytic Lympho...
    almost 5 years ago
    vexed's Avatar

    Decision Point

    Blood values are drifting too low. Will have to start treatment shortly. Opting for Rituxan alone rather than Rituxan/Chemo. It may be a better choice due to underlying heart disease. I am worried about the side effects

    0 Comments
  4. 4
    • vexed
    • Experience with Lymphoplasmacytic Lympho...
    over 4 years ago
    vexed's Avatar

    rituxan

    Drug or Chemo Therapy

    Blood values becoming too low---hemoglobin less than 8, RBC less than 2.5. Monoclonal antibody therapy proposed by doctor. Rituxan once a week for 8 weeks. First treatment in June 2012 a disaster---had to stop due to many side effects. Doctor added a steroid to counter side effects on weekly Rituxan treatments. This was successful but with a few mild side effects. Rituxan completed in August 2012. Now I'm waiting 2 months to see the results. If this is unsuccessful then chemo with Rituxan may be the next step. This scares the heck out of me. Rituxan is relatively mild compared with the side effects of many of the chemo drugs.

    Easy to Do: Not Specified
    Minimal Side Effects: Not Specified
    Minimal Impact to Daily Life: Not Specified
    1 Comment